{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.28","value":"390.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"CYCLE 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"428.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"499.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"198.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 10"},{"categories":[{"measurements":[{"groupId":"OG000","value":"269.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 11"},{"categories":[{"measurements":[{"groupId":"OG000","value":"346.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with RRMM received belantamab mafodotin at a dose of 2.5 mg/kg via IV infusion on Day 1 of each 28-day cycle in cycle 1, and at a dose of 1.9 mg/kg from cycle 2 onwards maximum up to disease progression. Along with belantamab mafodotin, Pomalidomide was administered orally as dose of 4 mg per day on Day 1 to Day 21 of 28-day cycles maximum up to disease progression. Dexamethasone orally as dose of 40 mg per day on Day 1, Day 8, Day 15, and Day 22 of each 28-day maximum up to disease progression.","id":"OG000","title":"Main Study - Part2: ArmB- Belantamab Mafodotin 2.5 mg/kg + Pomalidomide and Dexamethasone (Pom/Dex)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Cycle 2, Cycle 4, Cycle 10, Cycle 11 and Cycle 24","title":"Part 2: Arm B: C-EOI Following Repeat Dose Administration of Belantamab Mafodotin (Cys-mcMMAF)","type":"SECONDARY","unitOfMeasure":"pg/mL"}